Bio Pharma Dive
MARCH 16, 2022
Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing.
World of DTC Marketing
MARCH 14, 2022
It’s not only getting harder for small biotechs to find funding; too many have scaled up operations by adding employees too quickly, forcing them to lay off people as the path to new drug approvals gets more complicated. With two of its prized gene therapies on clinical hold, Bluebird, a small biotech company in Cambridge, is going through some hard times.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
MARCH 17, 2022
The sub-variant combines mutations from both Omicron and Delta
pharmaphorum
MARCH 17, 2022
The uptake of digital health tools during the pandemic has been enormous due to improved access they provide to healthcare. In this article, Ben Hargreaves asks whether there are gaps in those utilising these solutions and what action is being taken to address this. Digital health has a tremendous capacity to transform the healthcare industry, with the ability to provide easy access to a multitude of services and new types of therapies.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
MARCH 15, 2022
Stung by a stock market downturn, a number of biotechs are trimming spending and reprioritizing research to save cash. Passage's layoffs will reduce its workforce by 13%.
BioPharma Reporter
MARCH 14, 2022
The first participant has been dosed in a Phase 1 clinical trial of HIV trimer mRNA vaccine candidate mRNA-1574.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
MARCH 13, 2022
The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown. The new approval is for use in patients with BRCA-mutated, HER2-negative early-stage breast cancer who have already been treated with chemotherapy – either before or after surgery – and are at high risk of the disease coming back.
Bio Pharma Dive
MARCH 14, 2022
Lynparza is the first drug targeting BRCA mutations to be approved for use in early breast cancer, a decision that could lead to more genetic testing.
Scienmag
MARCH 18, 2022
Artificial intelligence advances how scientists explore materials. Researchers from Ames Laboratory and Texas A&M University trained a machine-learning (ML) model to assess the stability of rare-earth compounds. This work was supported by Laboratory Directed Research and Development Program (LDRD) program at Ames Laboratory. The framework they developed builds on current state-of-the-art methods for experimenting with […].
Pharma Times
MARCH 18, 2022
The hybrid of Delta and Omicron, known as ‘Deltacron’, has been identified in France, Denmark and the Netherlands
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Mirror
MARCH 18, 2022
HONG KONG, Sisram Medical Ltd (the “Company” or “Sisram”, stock code: 1696.HK; together with its subsidiaries referred as the “Group”), a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more, today announced its audited consolidated annual results for th
Bio Pharma Dive
MARCH 17, 2022
Biosimilar copies of Humira will arrive in the U.S. beginning early next year, testing both AbbVie and the market potential for knockoff biologic drugs.
Outsourcing Pharma
MARCH 14, 2022
The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.
Pharma Times
MARCH 14, 2022
In the coming months, an additional vaccine booster will be offered to those over 75, care home residents and to those over 12 who are most vulnerable
pharmaphorum
MARCH 15, 2022
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over full responsibility to its US counterpart. The changes to the terms of their longstanding collaboration on Aduhelm (aducanumab) means that Eisai’s profit-share converts to a simple royalty rate on revenues from 1 January next year.
Bio Pharma Dive
MARCH 17, 2022
The biotech claims the lipid nanoparticles used by Pfizer and Moderna for delivery of their coronavirus shots infringe on a key patent it holds.
BioPharma Reporter
MARCH 15, 2022
Sanofi and Blackstone today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to â300m ($329m) to accelerate development for subcutaneous formulation and delivery of anti-CD38 antibody Sarclisa to treat patients with multiple myeloma (MM).
Pharma Times
MARCH 16, 2022
Better treatment for conditions experienced by individuals who were exposed to alcohol before birth
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
MARCH 14, 2022
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing application. The US regulator has asked for additional clinical data, according to AZ, which said it remains committed to brining the drug to patients with the inflammatory condition, which results in the growth of nasal polyps in the nose that can sometimes require surgical intervention.
Bio Pharma Dive
MARCH 17, 2022
New study data add to evidence that checkpoint inhibitors can slow the return of lung tumors. But the results also leave some doubt over the best way to use the drugs.
Outsourcing Pharma
MARCH 14, 2022
An executive from the AI specialist discusses how recent advances have provided opportunities for industry professionals to champion new ways of thinking.
Pharma Times
MARCH 16, 2022
Patients who were bedridden for seven days or longer were at increased risk of depression and anxiety over the study period
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MARCH 17, 2022
Researchers in Germany are have found a possible link between mild COVID-19 infection and an increased risk of type 2 diabetes, although they caution the signal needs further investigation. The team from Heinrich Heine University in Dusseldorf and healthcare data science company IQVIA identified the possible correlation after analysing health records from 8.8 million patients registered at 1,171 health practices across Germany, including almost 36,000 who had been diagnosed with mild COVID-19.
Bio Pharma Dive
MARCH 15, 2022
Rather than fund development of a more convenient version of its blood cancer drug Sarclisa on its own, Sanofi has instead turned to Blackstone, which has fast become one of the sector's more active investors.
XTalks
MARCH 16, 2022
Canadian fast-food chain A&W is piloting the Zero Cup, a fully recyclable and compostable coffee cup designed by UK-based company Butterfly Cup. The environmentally-friendly cup is made entirely of paper and requires no lid, straw or plastic liner. A&W claims to be the first quick service restaurant (QSR) in North America to pilot the Butterfly Cup.
Pharma Times
MARCH 14, 2022
Site will include creating space for student accommodation, offices, retail outlets and restaurants
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
MARCH 15, 2022
A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias. According to the consortium – which includes drugmakers Biogen, Eisai, Eli Lilly and Merck & Co – there is a lack of measures that can be used to determine whether new therapies for Alzheimer’s are actually working.
Bio Pharma Dive
MARCH 14, 2022
The trial results were the most significant setback for the companies' four-year-old partnership and will likely force Nektar to cut costs.
BioPharma Reporter
MARCH 14, 2022
Pfizer Inc says it will maintain its supply of medicines to Russia but it will not initiate new clinical trials in the country, while Bayer is suspending investment projects and new-business development in that market.
Pharma Times
MARCH 18, 2022
With the significant increase in entries this year, the competition to name the finalists proved incredibly tough. The International Clinical Researcher judging panel, however, have made their decisions and the finalists have now been announced.
Expert insights. Personalized for you.
330 
Let's personalize your content